SB-742,457

From Wikipedia, the free encyclopedia
Jump to: navigation, search
SB-742,457
SB-742457-structure.png
Systematic (IUPAC) name
3-phenylsulfonyl-8-(piperazin-1-yl)quinoline
Clinical data
Legal status Uncontrolled
Routes Oral
Identifiers
CAS number 607742-69-8 YesY
ATC code None
PubChem CID 11256720
ChemSpider 9431746 N
ChEMBL CHEMBL1083390 N
Chemical data
Formula C19H19N3O2S 
Mol. mass 353.44 g/mol
 N (what is this?)  (verify)

SB-742,457 is a selective 5-HT6 receptor antagonist with cognition, memory, and learning-enhancing effects.[1][2][3][4] It is currently under development by GlaxoSmithKline for the treatment of Alzheimer's disease and has demonstrated preliminary efficacy in phase II clinical trials.[3][4][5]

References[edit]

  1. ^ Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). "5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 5 (3): 458–69. doi:10.1016/j.nurt.2008.05.008. PMID 18625457. 
  2. ^ Idris N, Neill J, Grayson B, et al. (January 2010). "Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms". Psychopharmacology 208 (1): 23–36. doi:10.1007/s00213-009-1702-5. PMID 19851757. 
  3. ^ a b Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. (December 2009). "Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease". Current Alzheimer Research 7 (5): 374–85. PMID 20043816. 
  4. ^ a b Rossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment". Current Topics in Medicinal Chemistry 10 (2): 207–21. doi:10.2174/156802610790411036. PMID 20166958. 
  5. ^ "Search of: SB-742457 - List Results - ClinicalTrials.gov".